RxDoctor Payments Data

Ovais Raza, MD

Interventional Cardiology · Bedford, INNPI 1386697761

Payments from drug & device makers

$686in general payments, 2019–2025

Across 31 payments — averaging $22.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$221
  • Abbott$197
  • Edwards Lifesciences$106
  • Amgen$38
  • Heartflow, Inc.$32
  • Arbor Pharmaceuticals, Inc.$31
  • plus $61 from 3 others

What the payments were for

  • Food & beverage$66397%
  • Education$233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$686 in reported general payments places this provider in the 10th percentile of 170 interventional cardiology providers in Indiana.

See all interventional cardiology providers in Indiana

Medicare billing

Part B allowed, 2024
$754,426
Medicare patients
1,106
Services billed
9,505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,556$1,450,926
XareltoRivaroxaban317$361,005
EntrestoSacubitril/Valsartan162$191,403
BrilintaTicagrelor47$36,527
Repatha SyringeEvolocumab31$26,676
Metoprolol Succinate1,987$26,264
JardianceEmpagliflozin20$25,323
Repatha SureclickEvolocumab16$25,133
NexletolBempedoic Acid24$19,154
VascepaIcosapent Ethyl43$17,197
Atorvastatin Calcium1,350$14,087
Diltiazem 24hr Er (Cd)Diltiazem Hcl336$12,051
Losartan Potassium1,324$11,280
Ezetimibe261$8,773
ClopidogrelClopidogrel Bisulfate724$8,415

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$25$191,403162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 170 interventional cardiology providers in Indiana.

Other interventional cardiology in Bedford

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →